Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Antiepileptic drug therapy for adults: when to initiate and how to choose Sirven JIMayo Clin Proc 2002[Dec]; 77 (12): 1367-75Although antiepileptic drugs (AEDs) are commonly used to control and prevent seizures, their long-term use carries a considerable risk of morbidity. The decision to start AEDs is made once the risks of further seizures outweigh the risks of treatment. Despite a large body of literature on the subject, this common clinical issue perplexes many practitioners because of its neurologic, psychological, and, at times, legal implications. Adding to the confusion is the recent approval of several new AEDs. This article summarizes the current evidence to support individual clinical decisions regarding initiation of AEDs in adults and considers the use of AEDs as seizure prophylaxis. Recently approved AEDs are discussed to help the practitioner understand when to initiate and how to choose the appropriate AED for the patient with seizures.|*Amines[MESH]|*Cyclohexanecarboxylic Acids[MESH]|*gamma-Aminobutyric Acid[MESH]|Acetates/adverse effects/therapeutic use[MESH]|Adult[MESH]|Anticonvulsants/adverse effects/*therapeutic use[MESH]|Carbamazepine/*analogs & derivatives/therapeutic use[MESH]|Epilepsy/*drug therapy[MESH]|Felbamate[MESH]|Fructose/*analogs & derivatives/therapeutic use[MESH]|Gabapentin[MESH]|Humans[MESH]|Isoxazoles/therapeutic use[MESH]|Lamotrigine[MESH]|Levetiracetam[MESH]|Nipecotic Acids/therapeutic use[MESH]|Oxcarbazepine[MESH]|Phenylcarbamates[MESH]|Piracetam/*analogs & derivatives/therapeutic use[MESH]|Propylene Glycols/adverse effects/therapeutic use[MESH]|Recurrence[MESH]|Risk Factors[MESH]|Tiagabine[MESH]|Topiramate[MESH]|Treatment Outcome[MESH]|Triazines/adverse effects/therapeutic use[MESH]|Zonisamide[MESH] |
